Phillip Bradshaw reader comments 18 Share this story When someone like Martin Shkreli fingers your company as greedy “vultures,” you know you’ve got problems. For pharmaceutical company Mylan, which hiked the price of life-saving EpiPens by 400 percent since it bought the product in 2007, Shkreli’s is just one of the voices in a chorus of scorn now...